Gordon Chang: If we don’t impose costs on the CCP for COVID-19, they will think they can do it again
Conservative columnist and East Asian expert Gordon Chang joined the “Sara Carter Show” podcast Thursday to discuss the latest developments on the Chinese Communist Party and its potential to start a war.
Chang warned that the Biden administration is taking steps in the wrong direction that may cause dangerous implications for the U.S.
“[The Biden administration] says we should cooperate with China on COVID-19. They want to rejoin the World Health Organization, these are the steps in the absolute wrong direction,” Chang tells Carter.
“This was deliberate, that means this was mass murder. And that has all sorts of implications that the Biden administration is not willing to consider.”
“China is developing pathogens that will leave the Chinese alone, but will attack foreigners. So that means the next disease from China could very well be something that kills civilizations outside China. And this shows you the maliciousness of the Chinese regime,” he continued.
Chang also warned that Xi Jinping, the head of the CCP, may cause another deadly attack.
“If we don’t impose costs on China for deliberately spreading this disease. Xi Jinping will just naturally think that he can do this again,” Chang said.
“We’re giving incentives to China, because we’re supporting the World Health Organization, which China controls, because we know that the way that China got its false narrative out to the world, was a January 9 statement, and a January 14 tweet from the World Health Organization, propagating the false narrative that COVID-19 was not readily transmissible from one human to the next. This was when WHO senior doctors knew that it was highly contagious, but their views were completely shut out by the political leadership of WHO and Biden has just agreed to shovel hundreds of millions of dollars a year to those people who were complicit in attack that has resulted in the deaths of hundreds of 1000s of Americans.”
Carter agreed with Chang that the CCP is trying to see how far they can push the Biden administration and asked him if he is concerned about Taiwan and India.
On Jan. 23, the Chinese military flew a large number of warplanes, including nuclear-capable H-6K bombers and fighter jets, to practice a run against the Theodore Roosevelt Carrier Strike Group.
“Which means that China was practicing attacks on us,” Chang explained.
“We don’t know where they’ll strike next, but we do know It’ll be against our friends and allies. And we need to meet them there. Because if we don’t, we’re gonna be fighting them over here.”
Gordon’s book, The Coming Collapse of China, explains why he believes the CCP will not be able to sustain its behavior for much longer.
“Right now, although China looks pretty fearsome, its economy is barely growing, if it’s growing at all,” Chang said. “It’s got a demographic collapse on the horizon. And Chinese leaders, we know from their propaganda, are seeing a closing window of opportunity. We know they’re arrogant, we know they’re insecure. We know they think they can push Biden around. They believe that they got to do this quickly.”
“We’ve got to worry about China now, because this is the critical time where China thinks it does have maybe the last chance to accomplish the historic objectives,” Chang warned.
“We know that China is effective. We know that they’re malicious, we know that they can accomplish their goals. And that means our country’s at risk.”
Follow Annaliese Levy on Twitter @AnnalieseLevy
You may like
FDA will work with China to import cancer drugs due to U.S. shortages
Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.
Foreign Desk News writes:
Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.
“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.
Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.
“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.
The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages. https://t.co/8XvOuJzSL4
— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023
Foreign Desk News adds:
The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.
You may like
Economy4 days ago
New York City Mayor Eric Adams Proposes Housing Asylum Seekers in Private Homes
Immigration3 days ago
Biden Administration to allow 40,000 asylum-seekers per month into US with mobile app
Economy4 days ago
Texas Gov Abbott aims to eliminate property taxes: ‘we must dream big’
International3 days ago
Saudi Arabia-Israel Deal Remains Biden’s Win to Lose